We also demonstrated a new potency of ezetimibe, an NPC1L1‐selective inhibitor clinically used against dyslipidemia, as a preventive and curative drug for steatosis (Figures 2 and 4), which will be of importance in terms of drug repositioning. The gene discussed is NPC1L1; the disease is metabolic syndrome.